Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1701, CAPOX, and Radiotherapy in Advanced Gastric Cancer
NCT07689851Phase 2Recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Jul 2026
- Primary completion
- Jul 2028
- Countries
- 1
01
Overview
A Phase 2 trial of retlirafusp alfa in gastric cancer (GC), gastroesophageal junction adenocarcinoma, sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Started Jul 2026; status: recruiting.
02
Drugs
retlirafusp alfa
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT07689851.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07689851.